phase i trial of prt3789, a smarca2 degrader, in smarca4-mutated solid tumors
Published 1 month ago • 93 plays • Length 2:16Download video MP4
Download video MP3
Similar videos
-
6:04
arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
-
1:28
structure based smarca2 protac design
-
1:10
opnme.com: acbi2, a smarca 2 protac to advance science
-
1:22
surpass: evaluating the next-generation of spear t-cell therapy
-
4:09
stk11/ keap1 co-mutant lung adenocarcinoma is dependent on scd1 to evade ferroptosis
-
8:18
esr mutations and resistance to endocrine therapy
-
3:21
one genetic cluster and two xp-v founder mutations, v. munford et al
-
50:28
the evolution of precision diagnostics in advancing treatment strategies of solid tumors
-
10:00
matching mutations in tumours to precision medicine improves survival
-
23:04
p. fratta - tdp-43: c-terminal mutations induce a splicing gain of function
-
1:38
dr. sartor on outcomes with 177lu-psma-617 after radium-223 in mcrpc
-
37:58
recombination, lineage-specific mutations and the emergence of sars-cov-2
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
2:34
sf3b1-mutant mds: a new disease subtype
-
0:59
giroctocogene fitelparvovec phase 1/2 trial
-
1:06
imaagen: phase 2 trial of abiraterone acetate for advanced prostate cancer
-
3:45
mutations matter
-
0:59
optishade™ class iii
-
5:56
randomized trial of evolut and sapien in patients with small annuli - pcr valves e-course 2020